Accelerating next-generation vaccine development for global disease prevention

Science

Volumn 340, Issue 6136, 2013, Pages

  Koff, Wayne C ^a   Burton, Dennis R ^b,d   Johnson, Philip R ^c   Walker, Bruce D ^b,d,e   King, Charles R ^a   Nabel, Gary J ^f   Ahmed, Rafi ^b,g   Bhan, Maharaj K ^h   Plotkin, Stanley A ^i,j  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f Sanofi Aventis   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Government of India   (India)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j Vaxconsult   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE; PATTERN RECOGNITION RECEPTOR; SMALLPOX VACCINE; TOLL LIKE RECEPTOR; VACCINE; WART VIRUS VACCINE; ANTIGEN; IMMUNOLOGICAL ADJUVANT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE CONTROL; DISEASE PREVALENCE; GENETIC VARIATION; IMMUNE RESPONSE; LITERATURE REVIEW; PUBLIC HEALTH; TUBERCULOSIS; VACCINATION;

ADAPTIVE IMMUNITY; ANTIBODY AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL RESEARCH; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG SAFETY; GENETIC VARIABILITY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEASLES; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REINFECTION; REVIEW; SEXUALLY TRANSMITTED DISEASE; SIMIAN IMMUNODEFICIENCY VIRUS; SMALLPOX; UNITED STATES; VACCINATION; VACCINE PRODUCTION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; DISEASE MODEL; DRUG DELIVERY SYSTEM; GENETICS; IMMUNOLOGY; INFECTION CONTROL; ISOLATION AND PURIFICATION; MALARIA; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; COMMUNICABLE DISEASE CONTROL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; MALARIA; TUBERCULOSIS; VACCINES;

MLCS; MLOWN;

EID: 84878356025     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1232910     Document Type: Review

References (87)

1. E. Jenner, The Origin of the Vaccine Inoculation (Shury, London, UK, 1801).
2. L. Pasteur, De l'attenuation du virus du choléra des poules. CR Acad. Sci. Paris. 91, 673 (1880).
3. D. Salmon, T. Smith, On a new method of producing immunity from contagious diseases. American Vet. Review. 10, 63 (1886).
4. J. F. Enders, T. H. Weller, F. C. Robbins, Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109, 85 (1949). doi: 10.1126/science.109.2822.85; pmid: 17794160
5. M. R. Hilleman, E. B. Buynak, R. E. Weibel, J. Stokes Jr., Live, attenuated mumps-virus vaccine. N. Engl. J. Med. 278, 227 (1968). doi: 10.1056/NEJM196802012780501; pmid: 4169706
6. S. A. Plotkin, J. D. Farquhar, M. Katz, F. Buser, Attenuation of RA 27-3 rubella virus in WI-38 human diploid cells. Am. J. Dis. Child. 118, 178 (1969). pmid: 5794813
7. A. B. Sabin, W. A. Hennessen, J. Winsser, Studies on variants of poliomyelitis virus. I. Experimental segregation and properties of avirulent variants of three immunologic types. J. Exp. Med. 99, 551 (1954). doi: 10.1084/jem.99.6.551; pmid: 13163327
8. J. E. Salk et al., Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am. J. Public Health Nations Health 44, 563 (1954). doi: 10.2105/AJPH.44.5.563; pmid: 13148396
9. M. R. Hilleman et al., Development and evaluation of the Moraten measles virus vaccine. JAMA 206, 587 (1968). doi: 10.1001/jama.1968.03150030043009; pmid: 5695578
10. S. Black et al.; Northern California Kaiser Permanente Vaccine Study Center Group, Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19, 187 (2000). doi: 10.1097/00006454-200003000-00003; pmid: 10749457
11. C. McNeil, Who invented the VLP cervical cancer vaccines? J. Natl. Cancer Inst. 98, 433 (2006). doi: 10.1093/jnci/djj144; pmid: 16595773
12. R. Schneerson, O. Barrera, A. Sutton, J. B. Robbins, Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152, 361 (1980). doi: 10.1084/jem.152.2.361; pmid: 6967514
13. D. A. D'Argenio, C. B. Wilson, A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design. Immunity 33, 437 (2010). doi: 10.1016/j.immuni.2010.10.011; pmid: 21029955
14. J. Ehreth, The value of vaccination: A global perspective. Vaccine 21, 4105 (2003). doi: 10.1016/S0264-410X(03)00377-3; pmid: 14505886
15. M. A. Miller, A. R. Hinman, in Vaccines, S. A. Plotkin, W. A. Orenstein, P. A. Offit, Eds. (Saunders, Philadelphia, 2008), pp. 1594-1610.
16. S. Green, A. Rothman, Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 19, 429 (2006). doi: 10.1097/01.qco.0000244047.31135.fa; pmid: 16940865
17. F. Sallusto, A. Lanzavecchia, K. Araki, R. Ahmed, From vaccines to memory and back. Immunity 33, 451 (2010). doi: 10.1016/j.immuni.2010.10.008; pmid: 21029957
18. M. J. McElrath, B. F. Haynes, Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33, 542 (2010). doi: 10.1016/j.immuni.2010.09.011; pmid: 21029964
19. J. C. Sacchettini, E. J. Rubin, J. S. Freundlich, Drugs versus bugs: In pursuit of the persistent predator Mycobacterium tuberculosis. Nat. Rev. Microbiol. 6, 41 (2008). doi: 10.1038/nrmicro1816; pmid: 18079742
20. C.-A. Siegrist, in Vaccines: Sixth Edition, S. A. Plotkin, W. Orenstein, P. A. Offit, Eds. (W.B. Saunders, London, 2013), pp. 14-32.
21. M. D. Simek et al., Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337 (2009). doi: 10.1128/JVI.00110-09; pmid: 19439467
22. D. R. Burton et al., A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396 (2012). doi: 10.1016/j.chom.2012.09.008; pmid: 23084910
23. B. F. Haynes, G. Kelsoe, S. C. Harrison, T. B. Kepler, B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30, 423 (2012). doi: 10.1038/nbt.2197; pmid: 22565972
24. R. Rappuoli, Reverse vaccinology. Curr. Opin. Microbiol. 3, 445 (2000). doi: 10.1016/S1369-5274(00)00119-3; pmid: 11050440
25. M. M. Giuliani et al., A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U.S.A. 103, 10834 (2006). doi: 10.1073/pnas.0603940103; pmid: 16825336
26. A. Sette, R. Rappuoli, Reverse vaccinology: Developing vaccines in the era of genomics. Immunity 33, 530 (2010). doi: 10.1016/j.immuni.2010.09.017; pmid: 21029963
27. C. Giefing et al ., Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J. Exp. Med. 205, 117 (2008). doi: 10.1084/jem.20071168; pmid: 18166586
28. M. J. Rodríguez-Ortega et al., Characterization and identification of vaccine candidate proteins through analysis of the group A streptococcus surface proteome. Nat. Biotechnol. 24, 191 (2006). doi: 10.1038/nbt1179; pmid: 16415855
29. R. S. Daum, in Vaccines: Sixth Edition, S. A. Plotkin, W. Orenstein, P. A. Offit, Eds. (W.B. Saunders, London, 2013), pp. 1161-1168.
30. D. R. Burton, Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2, 706 (2002). doi: 10.1038/nri891; pmid: 12209139
31. L. M. Walker et al.; Protocol G Principal Investigators, Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285 (2009). doi: 10.1126/science.1178746; pmid: 19729618
32. P. D. Kwong, J. R. Mascola, Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity 37, 412 (2012). doi: 10.1016/j.immuni.2012.08.012; pmid: 22999947
33. D. R. Burton, P. Poignard, R. L. Stanfield, I. A. Wilson, Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337, 183 (2012). doi: 10.1126/science.1225416; pmid: 22798606
34. T. Zhou et al., Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811 (2010). doi: 10.1126/science.1192819; pmid: 20616231
35. J. F. Scheid et al., Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633 (2011). doi: 10.1126/science.1207227; pmid: 21764753
36. M. Law et al., Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14, 25 (2008). doi: 10.1038/nm1698; pmid: 18064037
37. D. C. Ekiert et al., A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843 (2011). doi: 10.1126/science.1204839; pmid: 21737702
38. W. Schief, Epitope-focused vaccines. Retrovirology 9 Suppl. 2, S03.04 (2012).
39. Q. Zhang et al., Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res. 36, (Web Server), W513 (2008). doi: 10.1093/nar/gkn254; pmid: 18515843
40. A. H. Bakker, T. N. Schumacher, MHC multimer technology: Current status and future prospects. Curr. Opin. Immunol. 17, 428 (2005). doi: 10.1016/j.coi.2005.06.008; pmid: 15967654
41. D. L. Doolan et al., Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc. Natl. Acad. Sci. U.S.A. 100, 9952 (2003). doi: 10.1073/pnas.1633254100; pmid: 12886016
42. J. McMurry et al., Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinb.) 85, 95 (2005). doi: 10.1016/j.tube.2004.09.005; pmid: 15687033
43. M. Rosario et al., Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur. J. Immunol. 40, 1973 (2010). doi: 10.1002/eji.201040344; pmid: 20468055
44. W. Fischer et al., Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13, 100 (2007). doi: 10.1038/nm1461; pmid: 17187074
45. M. Moutaftsi et al., A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat. Biotechnol. 24, 817 (2006). doi: 10.1038/nbt1215; pmid: 16767078
46. M. Moutaftsi et al., Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. J. Immunol. 178, 6814 (2007). pmid: 17513729
47. J. Liu et al., Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457, 87 (2009). doi: 10.1038/nature07469; pmid: 18997770
48. P. A. Mudd et al., Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 491, 129 (2012). doi: 10.1038/nature11443; pmid: 23023123
49. S. H. Sheehy et al., ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20, 2355 (2012). doi: 10.1038/mt.2012.223; pmid: 23089736
50. M. D. Tameris et al.; the MVA85A 020 Trial Study Team, Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet 381, 1021 (2013). doi: 10.1016/S0140-6736(13)60177-4; pmid: 23391465
51. R. L. Coffman, A. Sher, R. A. Seder, Vaccine adjuvants: Putting innate immunity to work. Immunity 33, 492 (2010). doi: 10.1016/j.immuni.2010.10.002; pmid: 21029960
52. B. A. Beutler, TLRs and innate immunity. Blood 113, 1399 (2009). doi: 10.1182/blood-2008-07-019307; pmid: 18757776
53. A. Iwasaki, R. Medzhitov, Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987 (2004). doi: 10.1038/ni1112; pmid: 15454922
54. O. Takeuchi, S. Akira, Pattern recognition receptors and inflammation. Cell 140, 805 (2010). doi: 10.1016/j.cell.2010.01.022; pmid: 20303872
55. J. W. Huleatt et al., Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25, 763 (2007). doi: 10.1016/j.vaccine.2006.08.013; pmid: 16968658
56. H. Tighe et al., Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106, 124 (2000). doi: 10.1067/mai.2000.107927; pmid: 10887315
57. U. Wille-Reece et al., HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. U.S.A. 102, 15190 (2005). doi: 10.1073/pnas.0507484102; pmid: 16219698
58. C. L. Cooper, J. B. Angel, I. Seguin, H. L. Davis, D. W. Cameron, CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin. Infect. Dis. 46, 1310 (2008). doi: 10.1086/533467; pmid: 18444872
59. K. Chen, A. Cerutti, Vaccination strategies to promote mucosal antibody responses. Immunity 33, 479 (2010). doi: 10.1016/j.immuni.2010.09.013; pmid: 21029959
60. M. A. Liu, Immunologic basis of vaccine vectors. Immunity 33, 504 (2010). doi: 10.1016/j.immuni.2010.10.004; pmid: 21029961
61. W. C. Koff et al., Replicating viral vectors as HIV vaccines: Summary report from IAVI sponsored satellite symposium, International AIDS Society Conference, July 22, 2007. Biologicals 36, 277 (2008). doi: 10.1016/j. biologicals.2008.04.004; pmid: 18555698
62. S. G. Hansen et al., Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15, 293 (2009). doi: 10.1038/nm.1935; pmid: 19219024
63. K. Palucka, J. Banchereau, I. Mellman, Designing vaccines based on biology of human dendritic cell subsets. Immunity 33, 464 (2010). doi: 10.1016/j.immuni.2010.10.007; pmid: 21029958
64. L. Lai et al., Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J. Infect. Dis. 204, 164 (2011). doi:10.1093/infdis/jir199; pmid: 21628671
65. J. E. Boudreau et al., Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol. Ther. 17, 1465 (2009). doi: 10.1038/mt.2009.95; pmid: 19401673
66. B. Pulendran, S. Li, H. I. Nakaya, Systems vaccinology. Immunity 33, 516 (2010). doi: 10.1016/j.immuni.2010.10.006; pmid: 21029962
67. D. R. Hyduke, B. O. Palsson, Towards genome-scale signalling network reconstructions. Nat. Rev. Genet. 11, 297 (2010). doi: 10.1038/nrg2750; pmid: 20177425
68. T. D. Querec et al., Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116 (2009). doi: 10.1038/ni.1688; pmid: 19029902
69. X. Wu et al ; NISC Comparative Sequencing Program, Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593 (2011). doi: 10.1126/science.1207532; pmid: 21835983
70. R. N. Germain, Vaccines and the future of human immunology. Immunity 33, 441 (2010). doi: 10.1016/j.immuni.2010.09.014; pmid: 21029956
71. D. R. Bandura et al., Mass cytometry: Technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal. Chem. 81, 6813 (2009). doi: 10.1021/ac901049w; pmid: 19601617
72. P. K. Chattopadhyay, C. M. Hogerkorp, M. Roederer, A chromatic explosion: The development and future of multiparameter flow cytometry. Immunology 125, 441 (2008). doi: 10.1111/j.1365-2567.2008.02989.x; pmid: 19137647
73. K. R. Schulz, E. A. Danna, P. O. Krutzik, G. P. Nolan, Single-cell phospho-protein analysis by flow cytometry. Curr. Protoc. Immunol. Chapter 8, Unit 8 17 (2007).
74. M. M. Davis, A prescription for human immunology. Immunity 29, 835 (2008). doi: 10.1016/j.immuni.2008.12.003; pmid: 19100694
75. J. Seok et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program, Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 110, 3507 (2013). doi: 10.1073/pnas.1222878110; pmid: 23401516
76. M. G. von Herrath, G. T. Nepom, Lost in translation: Barriers to implementing clinical immunotherapeutics for autoimmunity. J. Exp. Med. 202, 1159 (2005). doi: 10.1084/jem.20051224; pmid: 16275758
77. J. D. Campbell et al ., CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans. J. Clin. Invest. 119, 2564 (2009). doi: 10.1172/JCI38294; pmid: 19726873
78. J. Mestas, C. C. Hughes, Of mice and not men: Differences between mouse and human immunology. J. Immunol. 172, 2731 (2004). pmid: 14978070
79. L. Quintana-Murci, A. Alcaïs, L. Abel, J. L. Casanova, Immunology in natura: Clinical, epidemiological and evolutionary genetics of infectious diseases. Nat. Immunol. 8, 1165 (2007). doi: 10.1038/ni1535; pmid: 17952041
80. E. Klechevsky et al., Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29, 497 (2008). doi: 10.1016/j.immuni.2008.07.013; pmid: 18789730
81. R. Ito, T. Takahashi, I. Katano, M. Ito, Current advances in humanized mouse models. Cell. Mol. Immunol. 9, 208 (2012). doi: 10.1038/cmi.2012.2; pmid: 22327211
82. B. Song et al., Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J. Virol. 79, 3930 (2005). doi: 10.1128/JVI.79.7.3930-3937.2005; pmid: 15767395
83. H. W. Virgin, J. A. Todd, Metagenomics and personalized medicine. Cell 147, 44 (2011). doi: 10.1016/j.cell.2011.09.009; pmid: 21962506
84. H. W. Virgin, E. J. Wherry, R. Ahmed, Redefining chronic viral infection. Cell 138, 30 (2009). doi: 10.1016/j.cell.2009.06.036; pmid: 19596234
85. D. I. Watkins, D. R. Burton, E. G. Kallas, J. P. Moore, W. C. Koff, Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14, 617 (2008). doi: 10.1038/nm.f.1759; pmid: 18535579
86. S. P. Buchbinder et al.; Step Study Protocol Team, Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881 (2008). doi: 10.1016/S0140-6736(08)61591-3; pmid: 19012954
87. M. M. Struck, Vaccine R&D success rates and development times. Nat. Biotechnol. 14, 591 (1996). doi: 10.1038/nbt0596-591; pmid: 9630948